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Introduction
Epilepsy is a common neurological disorder occurring in 0.4-1.0% of the population [1] .
Prenatal exposure to antiepileptic drugs (AEDs) is also common: 0.3-0.5% of all pregnant women have epilepsy and most use AEDs [2] . Women with epilepsy wanting to get pregnant or already pregnant have to make difficult decisions regarding use of AEDs. Seizures can cause greater harm to the mother and the fetus compared to the potential adverse effects of medication on embryonic development. Most are advised to continue using AEDs during pregnancy [3] . About 0.4% of all newborns have been exposed to AEDs in utero [4] .
The use of AEDs increases the risk of birth defects, such as heart defects, cleft lip or palate, dysmorphic disorders, defects in the limbs, defects in the genitals and urinary tract, and neural tube defects [5] [6] [7] . It is not fully known which AEDs play a role, but the risk seems especially related to valproate (VPA), higher doses and polytherapy [7] .
In utero exposure to AEDs is also associated with difficulties in cognitive and behavioral functioning. A correlation between prenatal VPA exposure and a lower verbal IQ (VIQ) has been found [8] [9] [10] [11] [12] [13] [14] [15] [16] . Delays in speech and motor development, conduct disorder, ADHD, and school problems have also been associated with prenatal exposure [9, [17] [18] [19] [20] . VPA exposure also appears to be related to an increased risk of autism spectrum disorders (ASD), as up to 11% of children were diagnosed with autism or Asperger syndrome [19, 21] .
Certain cognitive and behavioral developmental outcomes such as language development, memory, executive functioning, and child psychiatric problems, including ASD, can only be assessed later in childhood. Previous assessments of children of mothers with epilepsy were often inadequate as studies used retrospective designs or small samples. High quality prospective research is warranted to assess the safety of AED use during pregnancy regarding developmental outcomes. Therefore, the central project commission (EURAP CPC) developed a neurocognitive extension protocol (NCEP) to follow prospectively neurocognitive development of children exposed in utero [22] .
The NCEP includes an extensive neuropsychological screening, with VIQ at the age of six years as main outcome measure [22] .
As it is unknown whether effects of AEDs used during pregnancy are persistent or whether children catch up later, it's important to investigate long-term development prospectively. A systematic screening for attention deficit disorder, autism, and other behavioral problems, will provide better insight of behavioral development. It is not known how mothers with epilepsy experience the upbringing of their children, whether they feel competent to care, whether they experience parenting stress, and whether they receive social support. These topics need addressing as parenting and family factors could also contribute to developmental problems in children from special populations [23] [24] [25] . As in utero AED exposure seems a risk factor for child development, parenting and other family factors should be also examined as they may buffer against developmental problems or may help parents to cope better with child behavior [26] . Thus, further data on parenting as either a risk or a protective factor in the development of exposed children could contribute to fine-tuning treatment and guidance for these children and their families.
The aim of the Dutch EURAP & Development study is to extend the NCEP further: firstly through a longitudinal design with two measurement points at six or seven years and at eight or nine years of age, secondly, by including behavioral and family outcomes in addition to neurocognitive outcomes and lastly by also including children prenatally exposed to levetiracetam (LEV) as monotherapy, in addition to those exposed to monotherapy VPA, carbamazepine (CBZ) or lamotrigine (LTG).
Long-term neurocognitive and behavioral functioning after prenatal exposure
An increasing attention for the long-term neurocognitive and behavioral functioning of children exposed to AEDs in utero has developed since the NCEP started and prospective studies have reported [27] [28] [29] . A summary of these is provided in Table 4 . Studies vary by children's age and measures. Cognition appeared to be the main focus, with intelligence (IQ) or the developmental quotient (DQ) in younger children as primary measures. Most data is on children exposed to VPA, with only a few studies on the exposure to newer AEDs such as LEV [14, [30] [31] [32] .
Valproate exposed children. VPA exposure is most strongly associated with long-term cognitive and behavioral functioning. Compared to healthy children, children of mothers with epilepsy without prenatal exposure, exposure to other AEDs or standardized norms, infants and toddlers have been shown to have a developmental delay [14, 18, 30, [32] [33] [34] [35] , and lower IQ scores in school age [5, 10, 13, 31, [36] [37] [38] [39] [40] . Verbal functioning seems to be particularly affected [10, 13, 41] and, to a lesser extent, attention and memory functions [9, 42] . Children seem at risk for learning problems and have more frequent additional educational needs [17] .
Children seem more likely to show poor adaptive functioning in daily life [43] and are at an increased risk for neurodevelopmental disorders such as attention-deficit hyperactivity disorder (ADHD) and ASD [44, 45] . Elevated scores on the Child Autism Rating Scale (CARS) [46] suggest a dose-related effect [47] . Other studies have also found dose effects, with higher doses associated with more problems [13, 31, 36, 37, 48] . Some studies did not find significant neurocognitive or behavioral problems after prenatal VPA exposure [9, [49] [50] [51] . These different outcomes may be due to lower doses or small sample sizes.
Carbamazepine exposed children. Most studies did not find differences in cognitive functioning compared to controls [5, 9, 10, 37, [52] [53] [54] . Other studies, however, reported increased rates of developmental delay [18, 32, [55] [56] [57] . A recent meta-analysis showed that differences were associated with study methodologies [27] . No dose effect has been found for cognitive outcome measures [27] .
It seems that CBZ poses less of a risk for development compared with VPA. Children seem comparable to non-exposed on Full Scale IQ (FSIQ) [37] . Whether certain particular child characteristics or behavioral functioning are susceptible to CBZ exposure needs further studies [28] .
Lamotrigine exposed children. Many women of childbearing age use LTG [58] , but less research has been done into the long-term effects of prenatal exposure. LTG seems to have little or no effect on cognitive and behavioral development. Available reports do not suggest issues in the neurodevelopment of infants [32, 34, 57] . However, a higher risk was found for parenteral reports of impaired fine motor skills at age six months, and lower language skills at age 36 months [35] . Deficits have been found in nonverbal abilities, with lower scores on tasks of fine motor skills in early development compared to controls [34] , but after controlling for confounders (e.g. maternal IQ), this was not significant.
Studies in school-age children showed no difference in IQ compared to controls [37, 50] . No abnormal language development was found [41] . In comparison to VPA and CBZ, preschoolers exposed to LTG did not significantly differ from CBZ on cognitive functioning, and had less cognitive problems than VPA exposed preschoolers [12, 34, 57] . This was also true for school-aged children [13, 36, 59] . A risk for specific neurocognitive skills such as motor and sensory integration skills may exist for higher LTG dose [50] . Other studies did not find any dose effect [12, 13, 37] . Children seem to have less behavioral problems and better adaptive functioning compared to VPA at six years of age [48] . Compared to controls, no differences were found on behavior and attention measures [50] . No risk for neurodevelopmental disorders was seen [44] . Parents, however, reported increased concerns about autistic traits at 36 months [60] . No increased educational support was seen [37] .
Levetiracetam exposed children. Only a few studies have investigated the long-term effects of prenatal LEV exposure showing no impairments in neurodevelopment and IQ in infants, toddlers, and school-aged children [14, [30] [31] [32] . In comparison with children exposed to VPA, higher levels of early and preschool development were found, indicating less problems. No effect of dose was found.
Confounding factors
There are many other factors that may contribute to cognitive and behavioral development of exposed children. Controlling for potential confounders is crucial. Confounders have seldom been included [61] . Factors that may influence developmental outcomes are diverse and interrelated, and include aspects of maternal epilepsy and pregnancy, as well as child characteristics and features of the child's family environment [61] . Possible confounders are maternal IQ, socio-economic status, maternal age at birth, gestational age, maternal use of tobacco or alcohol, maternal preconception folate use and breastfeeding [62] .
Frequent convulsions during pregnancy have been found to be associated with reduced child cognitive functioning [5] , but this has not been replicated [10, 13] . Given the association between type of epilepsy and the choice of AED, the issue of confounding by indication persists: are relationships between long-term child development and AED exposure actually inherent to the type of maternal epilepsy? Of importance also is AED doses taken during pregnancy. Dose related deleterious effects have been found for VPA [7, 13] .
Family factors
As parenting stress, parental psychiatric problems, parenting and family functioning can act as mediating factors between earlier fetal exposure, the current epilepsy and the development of the child, we consider it important that these family factors are included in the research into children of mothers with epilepsy [63] .
Aim of this study
The purpose of the study is to address the following questions: 1. What is the nature and severity of cognitive and behavioral problems in children at ages six or seven and at follow-up at ages eight or nine? 2. Are there differences between the four AEDs in monotherapy and is there a dose effect? 3. What is the course of child developmental problems at ages eight or nine when compared to when children were six or seven? 4. Which additional epilepsy and family factors contribute to developmental problems in these children?
Methods

Study design and participants
This is a prospective longitudinal observational study, with assessors blinded to the AED exposures. Participants are mother-child pairs identified from the European Registry of Antiepileptic Drugs and Pregnancy database in the Netherlands (EURAP-NL). EURAP registers the prevalence of major congenital malformations following prenatal exposure to AEDs [7, 64] . Women with epilepsy are enrolled in EURAP-NL through referral by their health professional or by self-referral. Recruitment is national and preferably occurs within the first sixteen weeks of pregnancy facilitating prospective collection of information about epilepsy, seizures, health, and well-being during the pregnancy and other potential risk factors [64] .
In order to compare different types of AEDs, a child is only invited if its mother had been on monotherapy. Children receive a complete neuropsychological examination and parents complete behavioral and family factor questionnaires at T1 (six or seven years) and at T2 (eight or nine years).
Mothers and fathers complete a short-form intelligence test at T1 [65, 66] . The study was approved by the medical ethics committee of the Academic Medical Center (AMC: NL 45505.018.13) and registered with the Dutch trial register (www.trialregister.nl: NTR4800) prior to enrollment of the first participant.
Inclusion Criteria. Mother -child pairs must meet the following eligibility criteria: (1) enrolled in the EURAP-NL database with pregnancy ascertained and risk factors assessed prenatally, after delivery, or up until three years of age (possible exposure through breast feeding), (2) with the child born between 2007-2011, (3) prenatally exposed to CBZ, LTG, VPA, or LEV monotherapy during the entire pregnancy, (4) and aged between six years, 0 months and seven years, 11 months, at T1 and between eight years, 0 months and nine years, 11 months at T2, with two years (minimum 22 months and maximum 30 months) between the first and second neurocognitive assessment.
All pregnancies have also been submitted to the central EURAP registry in Milan. Every effort will be made to enroll all consecutive mother-child pairs. Information about reasons for not participating are recorded and analyzed to minimize possible selection bias. Before the start of the study, and each subsequent year, addresses are checked in the municipal administration.
Exclusion criteria. Participants are excluded if: (1) the mother is unable to take care of the child (e.g., due to severity of epilepsy), (2) the child has a known chromosomal/genetic syndrome or prematurity (gestational age less than 37 weeks), or (3) there are factors other than AED exposure which significantly modify child development, such that reliable assessment is not possible.
Sample size. The sample size was calculated to enable us to find differences in change between children of mothers who use different AEDs. With a medium expected effect size of f (V) = 0.25 (e.g., a 0.5 SD difference between the most and least changing groups and a 0.5 autocorrelation [67] ), a total sample size of 179 suffices for a 80% chance of finding a group by time interaction effect at a 5% level of significance, whereas a sample size of 231 suffices for a 90% chance to find a medium sized effect. Other analyses require smaller sample sizes.
A total of 517 children enrolled in EURAP-NL and born between 2007 and 2011 is invited ( Table 1 ). Assuming that half will agree to join the study, we expect to include about 260 children and their parents. Based on earlier experiences, we assume that parents are interested in, but may also be concerned about, the development of their child, and in general willing to participate.
Procedure
Participants who meet the inclusion criteria receive an invitation letter around the time of the child's sixth birthday. Parents may use a reply card, email or the website (www.sein.nl/eurap) to indicate whether or not they want to participate. Families who do not respond receive a reminder after one month. If no reply has been received after three months, families are contacted by telephone to ask whether they are willing to participate. Parents who do not wish to participate are asked to complete the survey part of the study by completing online questionnaires. If the child has had a psychological examination within the last year, we ask parents for the reports (e.g., IQ test). For families willing to participate, an appointment is made at one of our test sites for the first assessment with, ideally, both parents and the child. If the father is unable to attend, he is asked to complete the online questionnaires at home.
The study is carried out within one day, from 9:30 in the morning until approximately 15:00 hours (Daily schedule, Table 3 ). A fixed test sequence is used for children and parents (Figure 2 
Measures
The study examines different domains of development from a bio-ecological perspective [68] :
(1) child neurocognition, (2) child behavior, and (3) Secondary outcome measures (3) are parenting stress, parental psychiatric symptoms, impact of maternal epilepsy on self and family, quality of parent child relationship, parenting and family functioning. Table 2 presents an overview of the measures and the time points of study assessments.
Statistical analyses
The nature and severity of cognitive and behavioral problems in children at ages six or seven (T1) and at follow-up at ages eight or nine (T2) are investigated through descriptive analyses, and by comparing the mean scores of prenatally exposed children with normative mean scores. This gives a comprehensive description of the neurocognitive and behavioral development of prenatally exposed children.
Regression analysis will be used to investigate whether there are significant differences between the children from the four AED groups at T1 as well as T2, and whether there is a dose effect, while taking into account potential confounders. In order to select confounding factors, we first check the relationships of confounders with medication as well as with the outcome variables. To examine the course of child developmental problems at ages eight or nine when compared to children aged six or seven, multilevel multiple regression analyses are conducted with repeated measures 'nested' within children. Factors such as epilepsy, parenting, family factors that may contribute to developmental problems are included in the models to investigate interaction effects.
Discussion
We hope to obtain insights in neurocognitive, behavioral and family functioning of children who were exposed to AEDs in pregnancy. Findings may help future parents to minimize developmental problems or to cope better with child behavior [26] . We anticipate that strengths are the extensive developmental, neurocognitive and behavioral measurements of both children and parents, with standardized tests and trained assessors blinded to AED exposure. This study extends the NCEP protocol by including children exposed to LEV, which is increasingly prescribed for pregnant women with epilepsy. LEV seems to be associated with fewer malformations after birth [69] , but the long-term neurocognitive and behavioral outcomes should also be investigated [30, 31] .
The follow up on children at eight or nine years allows us to investigate whether their development will improve or deteriorate over time. To date, no studies are available on the long-term outcome for these AEDs in relation to epilepsy and family factors. Examining children at an older age allows us to examine areas of neurocognitive functioning, such as executive functioning, which emerge only later in development. Previous studies have included children up to six years only, or were cross-sectional, using a wider age range [9, 13, 15, 31, 37, 42, 51 ].
An anticipated limitation is that the presence of early developmental concerns in children may lead to a bias in the participation in the study. Families of children who experienced problems at a younger age and who may already have been diagnosed may not want to participate. The opposite may also be conceivable, that parents who experience problems with their child are more likely to participate.
Our study is expected to contribute to clinical practice, offering treating neurologists and other health care professionals new information to help fine-tuning the counselling of women with epilepsy, before, during, and after pregnancy. The study may not only be of help with the choice of a suitable AED but may also reveal which topics associated with the upbringing of the child should be discussed. Professionals counselling mothers with epilepsy may use the outcomes to ask about family life, parenting, and child development. As such, mothers with epilepsy can be continuously given appropriate support and referral if needed. We hope that this will contribute to the quality of life in mothers with epilepsy, their children, and their families. Finally, by publishing this study protocol, we intend to provide other researchers and healthcare professionals with the tools to set up future studies into child developmental outcome in the context of having been exposed to AEDs and growing up with a mother with epilepsy. Note. The sequence of subtests taken may have an impact on the test results, e.g., because of initial shyness of the child at the beginning of the day, or fatigue occurring during the course of the day. Therefore, the sequence of subtests was hold the same for all children. This may also help to repeat our study. Study population 517
Sample size 257 Table 2 . In both comparison between AED vs control and VPA-LTG vs control, control children performed better in all areas. No significant differences were found between VPA and LTG. But more differences were found between VPA and control than LTG and control. Compared to control group VPA exposed children scored lower on motor and sensory tasks, and according to parent report higher on behavior / attention problems. LTG exposed children had lower scores on motor and sensory tasks when compared to control children, but did not have behavior / attention problems. (14) 5-9 years WISC-IV/ WPSI-III NEPSY BASC Prenatal exposure to LEV and TPM were not associated with reductions in child cognitive abilities, and adverse outcomes were not associated with increasing dose. Increasing dose of VPA was associated with poorer FSIQ, verbal and nonverbal abilities. Doses of 800 mg VPA was significantly associated with a 10.6-point reduction in FSIQ, 11.2-point reduction in verbal abilities, and 11.1-point reduction in nonverbal abilities. VPA was also associated with poorer outcomes on expressive naming index as well as behavioral variables of withdrawal, adaptability, and daily living skills but not on other measures of language, memory, attention and executive functioning, or behavioral outcomes. 
Dutch EURAP & Development Study constructs with concomitant child-and parent-measures
Construct
Indian IQ test
Indian language test FSIQ and language scores were significantly lower for CME (87.7 and 73.4) compared to control children (93.0 and 83.2). CME scored poor on all subtests of language but their impairment was confined to only some of the subtests of IQ. Maternal education and maternal IQ significantly correlated with low IQ and language scores for CME whereas type of epilepsy, seizures during pregnancy or low birth weight did not. Polytherapy and higher dose of AEDs were associated with significant impairment in outcome measures. The FSIQ or language score of CME did not vary significant according to monotherapy exposure. 81% reported behavioral problems, 39% with hyperactivity or poor concentration of whom 7% had a diagnosis of ADHD. 60% reported two or more autistic features, of whom four had a diagnosis of autism and two of Asperger's syndrome. 77% had learning difficulties, 81% speech delay, 60% gross motor delay, and 42% fine motor delay.
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Mawer et al. Developmental delay occurred in 24% of exposed children, compared with 11% of non-exposed sibs. The frequency of developmental delay in PB was not significantly different from non-exposed, while the frequencies for those exposed to CBZ, VPA, PHT, and polytherapy were significantly higher. Of exposed children 20% had behavior disorders (vs 5% of nonexposed). Behavior disorders were not significantly more common in exposed children, but analysis of specific drug exposure groups showed significantly more behavior problems in CBZ and VPA monotherapy, and polytherapy group. Prevalence of low intelligence (FIQ < 80) was 19%, and exceptionally low intelligence (FIQ < 70) 10% in VPA exposed children. Children exposed to CBZ and children of WWE not exposed to AED during pregnancy had all at least low average intelligence. Mean IQs of children exposed to VPA were 11-17 points lower than CBZ and nonexposed group, however mean difference of children on FIQ, VIQ and PIQ were not statistically significant. On NEPSY subtests VPA exposed children performed significantly lower on Memory for Faces compared with CBZ and lower than nonexposed on List Learning. 62% of children exposed to VPA and 15% each in the CBZ-exposed and non-exposed groups required educational support. Children exposed to VPA had higher scores in all the domains analyzed, indicating behavioral problems, but because of small number, these differences did not reach statistical significance. However, results in two domains (Social Problems, p = 0.07, and Cognitive Problems/Inattention, p = 0.09) indicated a trend for the VPA-exposed children to have more behavioral problems. CBZ-exposed and non-exposed children had very similar scores, and no statistical differences were found between these two groups. VPA exposure was associated with high levels of parental stress induced by child maladaptive behavior. VPA exposed children also had poorer daily living skills and socialization skills. VABS and PSI were strongly affected by child FSIQ; however, no significant differences were found between the groups on FSIQ. Despite similar IQ CME scored significantly lower than control children on measures of attention, memory, and fine-motor function. Deficits were more marked in but not limited to the subset of the study group exposed to maternal AEDs. Group differences on auditory attention were found only in younger children. VPA-exposed children had lower scores on sentence repetition and on the more demanding part of auditory attention, than other children in the study group, suggesting weaknesses in working memory. IQ, attention and memory of CME were significantly lower compared to control children. Predictors of low FSIQ were AED dose, maternal IQ, and parental education. FSIQ of CME (77.9) was with 8.5 points significantly lower than controls (86.4). FSIQ of polytherapy was significantly lower than monotherapy group. In monotherapies, PB was significantly associated with low IQ, whereas VPA had FSIQ comparable to CBZ, LTG and PHT. This apparent difference is suggested to be possible due to low dose of VPA (M 480.06 mg/day) .
